Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia

J Med Chem. 1997 Sep 26;40(20):3141-3. doi: 10.1021/jm970364a.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists*
  • Adrenergic alpha-Antagonists / chemical synthesis*
  • Adrenergic alpha-Antagonists / therapeutic use
  • Animals
  • Dogs
  • Humans
  • Indoles / chemical synthesis*
  • Indoles / therapeutic use
  • Isoindoles
  • Male
  • Models, Chemical
  • Prazosin / analogs & derivatives
  • Prazosin / therapeutic use
  • Prostatic Hyperplasia / drug therapy*
  • Pyrimidinones / chemical synthesis*
  • Pyrimidinones / therapeutic use
  • Rats
  • Receptors, Adrenergic, alpha-1
  • Sulfonamides / therapeutic use
  • Tamsulosin

Substances

  • A 131701
  • ADRA1A protein, human
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Indoles
  • Isoindoles
  • Pyrimidinones
  • Receptors, Adrenergic, alpha-1
  • Sulfonamides
  • Terazosin
  • Tamsulosin
  • Prazosin